Boatin B A, Hougard J M, Alley E S, Akpoboua L K, Yaméogo L, Dembélé N, Sékétéli A, Dadzie K Y
World Health Organization/Onchocerciasis Control Programme in West Africa, Ouagadougou, Burkina Faso.
Ann Trop Med Parasitol. 1998 Apr;92 Suppl 1:S46-60.
For many years there was no suitable drug available for the control of onchocerciasis. The advent of Mectizan (ivermectin, MSD; an effective microfilaricide), its registration in October 1987 for the treatment of human onchocerciasis, and its suitability for large-scale application were major break-throughs in the control of human onchocerciasis via chemotherapy. Several studies, both fly-feeding experiments and community trials, have established that Mectizan treatment causes a significant reduction in the transmission of infection. Although long-term treatment in some isolated foci (such as occur in the New World and in some hypo- and meso-endemic areas elsewhere) appears to interrupt transmission, more prolonged treatment is required to prove if transmission can be stopped. Advantage could be taken of the significant impact of Mectizan on transmission by giving treatment while or just before transmission by blackflies is most intense.
多年来，一直没有合适的药物可用于控制盘尾丝虫病。美迪善（伊维菌素，默克雪兰诺公司生产；一种有效的杀微丝蚴剂）的出现、其于1987年10月获准用于治疗人类盘尾丝虫病以及其适用于大规模应用，是通过化疗控制人类盘尾丝虫病方面的重大突破。多项研究，包括喂蝇实验和社区试验，均已证实美迪善治疗可显著减少感染传播。尽管在一些孤立病灶（如在新大陆以及其他一些低度和中度流行地区出现的病灶）进行长期治疗似乎可阻断传播，但仍需要更长时间的治疗来证明是否能够阻断传播。可利用美迪善对传播的显著影响，在蚋传播最为强烈之时或之前进行治疗。
